Q4 2024 Management View CEO Mark Newcomer highlighted that Paysign achieved exceptional growth in its patient affordability business in 2024, with annual revenue increasing by 212% to $12.7 million.

Cooper Flagg #2 of the Duke Blue Devils defends Jason Asemota #5 of the Baylor Bears during the second round of the 2025 NCAA ...

The "Needle Free Drug Delivery Devices Market Industry Trends and Forecasts to 2035 -- Distribution by Type of Device, Route ...

The average cost for a Big Pharma to develop a drug in 2024 was $2.23 billion, up from $2.12 billion the year before. | The ...

A leading U.S.-based drug delivery device company known for its strong global commercial presence recognized this opportunity ...

The trial results are critical, as it brings Eli Lilly’s pill one step closer to becoming a new, needle-free alternative for ...

Codix Pharma's journey in the Nigerian pharmaceutical industry is one of innovation, strategic leadership, and a bold ...

Johnson & Johnson’s Stelara, Regeneron’s Eylea and Amgen’s Prolia are just some of the drugs facing off against new ...

Gozellix®, after radiolabeling with 68 Ga, is indicated for PET scanning of PSMA positive lesions in men with prostate cancer who have suspected metastasis and are candidates for initial definitive ...

A new search tool unveiled Friday increases public access to information about the connections between advisors to the ...